Imezemic 1000 Tablet contains Imeglimin 1000mg, an oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin is a novel tetrahydrotriazine compound that improves glycemic control by targeting mitochondrial bioenergetics, thereby enhancing insulin sensitivity and promoting glucose-dependent insulin secretion. It acts on multiple pathophysiological defects associated with type 2 diabetes, including impaired insulin secretion and insulin resistance in peripheral tissues. Imezemic 1000 is typically prescribed as monotherapy or as an adjunct to other antidiabetic agents when diet and exercise alone do not provide adequate glycemic control. Clinical studies have demonstrated that Imeglimin effectively reduces HbA1c levels with a favorable safety profile and low risk of hypoglycemia. The tablet should be administered orally once or twice daily, with or without food, as directed by a healthcare professional. Dose adjustments may be necessary in patients with renal impairment. Common adverse effects include mild gastrointestinal symptoms such as nausea and diarrhea, which are generally transient. Imezemic 1000 should be used cautiously in patients with hepatic dysfunction and is contraindicated in individuals with known hypersensitivity to Imeglimin or any tablet components. Regular monitoring of glycemic parameters is recommended to assess therapeutic efficacy and safety.